N/A
Completed N=69
Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED
Substance Withdrawal Syndrome
Source: ClinicalTrials.gov NCT02643355 ↗
Enrolled (actual)
69
Serious AEs
0.0%
Results posted
Jul 2019
Primary outcomePrimary: Number of Participants That Received Rescue Medication for Withdrawal Symptoms Within 1 Hour — 9; 19 Participants
Summary
Withdrawal from opioids is a clinical scenario that emergency department physicians encounter frequently. Patients who present with opioid withdrawal display symptoms such as agitation, anxiety, myalgias, abdominal pain, diarrhea, nausea, and vomiting. Currently, the standard treatment for opioid withdrawal is clonidine (an alpha-2 adrenergic agonist), as well as supportive cares (anti-emetics, intravenous fluids). Olanzapine is an atypical antipsychotic that is given frequently in the ED for many of the same symptoms that are seen in patients who are experiencing opioid withdrawal, however its use in this toxidrome has never been studied. The hypothesis of this study is that olanzapine is a safe and efficacious option when compared to clonidine for the treatment of opioid withdrawal in the emergency department.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants That Received Rescue Medication for Withdrawal Symptoms Within 1 Hour |
9; 19 | — |
| SECONDARY Clinical Opiate Withdrawal Scale Score at 1 Hour Post Medication |
5.3; 6.7 | — |
| SECONDARY Clinical Opiate Withdrawal Scale Score at 2 Hours Post Medication |
4.8; 3.7 | — |
| SECONDARY Clinical Opiate Withdrawal Scale Score at the Time of Disposition |
4.3; 3.6 | — |
Eligibility Criteria
Inclusion Criteria
- Any patients who present to the emergency department where the providers are concerned for opioid withdrawal contributing to their symptoms on presentation is eligible for inclusion.
Exclusion Criteria
- Age less than 18
- Allergy to either medication (olanzapine, clonidine)
- Inability to give informed consent
- Known pregnancy
Data sourced from ClinicalTrials.gov (NCT02643355). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.